Synthon announces European approvals for Eplerenone

19-Sep-2011 - Netherlands

Synthon announced that it has successfully concluded multiple registration procedures for the cardiovascular drug Eplerenone. Synthon has obtained regulatory clearance for the product in nine European countries, for both 25 and 50 mg film coated tablets.

Synthon's Eplerenone is a fully generic and bioequivalent version of Pfizer’s Inspra® tablets.

European sales of Eplerenone were 109 million Euros (MAT June 2011) based on IMS Midas data. Synthon’s Eplerenone is part of a rich pipeline of research projects and pending regulatory applications.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances